Prevention of atrial fibrillation
135 results
66 - 135
Indications for and implementation of anticoagulant therapy in atrial fibrillation 
Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks: Cochrane systematic review- Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks: Cochrane systematic review
- Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter: Cochrane systematic review
- Direct oral anticoagulants
- Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack: Cochrane systematic review
- Antithrombotic agents in primary health care
Colchicine prevents postpericardiotomy syndrome following cardiac surgery- AHA guideline for secondary stroke prevention
- Electrical cardioversion
- Bleeding risk with warfarin high among elderly, especially older than 80
- Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
- No reduction in stroke recurrence with apixaban vs aspirin in patients with cryptogenic stroke and atrial cardiopathy (ARCADIA)
- Dual therapy with dabigatran and clopidogrel preferred after PCI for patients with AF (RE-DUAL PCI)
- Aortic stenosis
- Factor Xa inhibitors versus vitamin K antagonists for preventing embolism in patients with atrial fibrillation
- Cerebral infarction (ischaemic stroke)
- Direct oral anticoagulants versus vitamin K antangonists in non-valvular atrial fibrillation
- Warfarin superior to antiplatelet treatment for A Fib
- Mitral regurgitation
- Rivaroxaban + clopidogrel causes somewhat less bleeding than triple therapy in patients with AF undergoing PCI
- Closure vs. medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or TIA
- Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin: Cochrane systematic review
- Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
- Hypertrophic cardiomyopathy
- Dilated cardiomyopathy
- Dabigatran versus vitamin K antagonists in non-valvular atrial fibrillation
- Low-dose aspirin not effective for primary prevention of CV events (again) and increases risk of serious bleeding
- Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non‐valvular atrial fibrillation
- Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack: Cochrane systematic review
- Transient ischaemic attack (TIA)
- Dual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular block
- Perioperative beta‐blockers for preventing surgery‐related mortality and morbidity in adults undergoing cardiac surgery
- Niacin not effective in CAD with low HDL cholesterol (AIM-HIGH)
- Anticoagulants versus antiplatelet agents for acute ischaemic stroke: Cochrane systematic review
- Discontinuing warfarin therapy indefinitely after GI bleeding assoc with worse outcomes
- Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
- Prevention of venous thromboembolism
- Preoperative statin therapy for adults undergoing cardiac surgery
- Comparable benefits and harms of anticoagulant and antiplatelet treatment in patients with PFO and cryptogenic stroke
- Antiplatelet and anticoagulation for patients with prosthetic heart valves
- 2023 American Geriatric Society update on potentially inappropriate medication use in the elderly (Beers List)
- Perioperative beta‐blockers for preventing surgery‐related mortality and morbidity in adults undergoing non‐cardiac surgery
- Prophylactic use of inotropic agents for the prevention of low cardiac output syndrome and mortality in adults undergoing cardiac surgery
- Icosapent ethyl reduces risk of CV death in patients with CV disease, low LDL, and high triglycerides (REDUCE-IT)
- Antiplatelet therapy for prevention of death, myocardial infarction, and stroke
- Colchicine for the primary prevention of cardiovascular events
- Anticoagulants for people hospitalised with COVID‐19
- Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
- Lumbar puncture
- Preoperative assessment
- Hypertension: investigations, treatment initiation and non-pharmacological treatment
- Natriuretic peptide‐guided treatment for the prevention of cardiovascular events in patients without heart failure
- Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults: Cochrane systematic review
- Deep vein thrombosis